Non-medical use of prescription opioids and prescription opioid-related harms: Why so markedly higher in North America compared to the rest of the world?

Addiction

Volumn 109, Issue 2, 2014, Pages 177-181

  Fischer, Benedikt ^a,b,c   Keates, Annette ^d   Bühringer, Gerhard ^e,f   Reimer, Jens ^g   Rehm, Jürgen ^b,c,e  

^a SIMON FRASER UNIVERSITY   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f IFT INSTITUT FÜR THERAPIEFORSCHUNG   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Harms; Health systems; International comparison; Medical culture; Misuse; Policy; Prescription opioids

Indexed keywords

NARCOTIC ANALGESIC AGENT;

CANADA; DRUG MISUSE; HEALTH; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; OPIOID-RELATED DISORDERS; ORGANIZATION AND MANAGEMENT; PATIENT SATISFACTION; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANALGESICS, OPIOID; CANADA; DELIVERY OF HEALTH CARE; GLOBAL HEALTH; HEALTH POLICY; HUMANS; OPIOID-RELATED DISORDERS; PATIENT SATISFACTION; PRESCRIPTION DRUG MISUSE; UNITED STATES;

EID: 84892399830     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12224     Document Type: Article

References (62)

1. Holmes D. Prescription drug addiction: the treatment challenge. Lancet 2012; 379: 17-18.
2. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2011. Vienna: United Nations Publications; 2011. Sales no. E.11.XI.10. Available at: http://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf (accessed 4 February 2013) (Archived at http://www.webcitation.org/6EBfpRr1C on 4 February 2013).
3. European Monitoring Center on Drugs and Drug Abuse (EMCDDA). Annual Report 2011: The State of the Drugs Problem in Europe. Luxembourg: EU Publications; 2011. Available at: http://www.emcdda.europa.eu/publications/annual-report/2011 (accessed 4 February 2013) (Archived at http://www.webcitation.org/6EBg8S0BP on 4 February 2013).
4. Manchikanti L., Fellows B., Ailinani H., Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010; 13: 401-435.
5. Substance Abuse and Mental Health Services Administration (SAMHSA). State Estimates of Substance Use and Mental Disorders from the 2008-2009 National Surveys on Drug Use and Health. NSDUH Series H-40, HHS Publication no. (SMA) 11-4641. Rockville, MD: SAMHSA; 2011.
6. Fischer B., Ialomiteanu A., Boak A., Adlaf E., Rehm J., Mann R. E. Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. Drug Alcohol Rev 2013; 32: 276-287.
7. Fischer B., Rehm J., Patra J., Firestone Cruz M. Changes in illicit opioid use profiles across Canada. Can Med Assoc J 2006; 175: 1385-1387.
8. Sigmon S. Characterizing the emerging population of prescription opioid abusers. Am J Addict 2006; 15: 208-212.
9. Fischer B., Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician 2012; 15: ES191-203.
10. Volkow N. D., McLellan T. A. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011; 305: 1346-1347.
11. Paulozzi L., Jones C., Mack K., Rudd R., Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. Morb Mortal Wkly Rep 2011; 60: 1487-1492.
12. Dhalla I. A., Mamdani M. M., Sivilotti M. L., Kopp A., Qureshi O., Juurlink D. N. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Can Med Assoc J 2009; 181: 891-896.
13. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-1985.
14. Casati A., Sedefov R., Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012; 18: 228-245.
15. Leong M., Murnion B., Haber P. S. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009; 39: 676-681.
16. Reissner V., Kokkevi A., DiFuria L., Schiffano F., Room R., Stohler R. etal. Drug consumption, health service use and outcome in opiate addicts in Europe: an 18-month follow-up from Athens to Zurich. Eur Psychiatry 2008; 23: S74-75.
17. Myers B., Siegfried N., Parry C. D. H. Over-the-counter and prescription medicine misuse in Cape Town-findings from specialist treatment centres. S Afr Med J 2003; 93: 367-370.
18. Iravani F. S., Akhgari M., Jokar F., Bahmanabadi L. Current trends in tramadol-related fatalities, Tehran, Iran 2005-2008. Subst Use Misuse 2010; 45: 2162-2171.
19. Rintoul A. C., Dobbin M. D. H., Drummer O. H., Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2011; 17: 254-259.
20. Ojanperä I., Gergov M., Liiv M., Riikoja A., Vuori E. An epidemic of fatal 3-methylfentanyl poisoning in Estonia. Int J Legal Med 2008; 122: 395-400.
21. Degenhardt L., Bucello C., Calabria B., Nelson P., Roberts A., Hall W. etal. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 2011; 117: 85-101.
22. Fischer B., Nakamura N., Urbanoski K., Rush B., Rehm J. Correlations between population levels of prescription opioid use and prescription opioid-related substance use treatment admissions in the USA and Canada since 2001. Public Health 2012; 126: 749-751.
23. Kuehn B. M. Opioid prescriptions soar. JAMA 2007; 297: 249-251.
24. Wisniewski A. M., Purdy C. H., Blondell R. D. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. J Addict Dis 2008; 27: 1-11.
25. Manchikanti L., Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008; 11: S63-88.
26. International Narcotics Control Board (INCB). Narcotic Drugs Technical Report: Estimated World Requirements for 2012-Statistics for 2010. Sales no. T.12.XI.2. New York: United Nations Publications; 2012. Available at: http://www.incb.org/incb/en/narcotic-drugs/Technical_Reports/2011/narcotic-drugs-technical-report_2011.html (accessed 4 February 2013) (Archived at http://www.webcitation.org/6EBgFnaok on 4 February 2013).
27. Medina-Mora M. E. The barriers separating low- and middle-income countries from legal painkillers. Addiction 2012; 107: 863-864.
28. Size M., Soyannwo O. A., Justins D. M. Pain management in developing countries. Anaesthesia 2007; 62: 38-43.
29. Bosnjak S., Maurer M. A., Ryan K. M., Leon M. X., Madiye G. Improving the availability and accessibility of opioids for the treatment of pain: the International Pain Policy Fellowship. Support Care Cancer 2011; 19: 1239-1247.
30. Cherny N. I., Baselga J., de Conno F., Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 2010; 21: 615-626.
31. Wang J., Christo P. The influence of prescription monitoring programs on chronic pain management. Pain Physician 2009; 12: 507-515.
32. Morden N. E., Zerzan J. T., Rue T. C., Heagerty P. J., Roughead E. E., Soumerai S. B. etal. Medicaid prior authorization and controlled-release oxycodone. Med Care 2008; 46: 573-580.
33. Schubert I., Ihle P., Sabatowski R. Increases in opioid prescriptions in Germany, 2000-2010. Deutsches Ärzteblatt 2013; 110: 45-51.
34. Fischer B., Jones W., Krahn M., Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf 2011; 20: 1269-1277.
35. Böger R. H., Schmidt G. Analgetika. In: Schwabe U., Paffrath D., editors. Pharmaceuticals Prescription Report 2011: Current Data, Costs, Trends and Comments, 1st edn. Berlin: Springer-Verlag; 2011, p. 261-277.
36. Ialomiteanu A., Adlaf E. M., Hamilton H., Mann R. E. 2011 CAMH Monitor eReport: Addiction and Mental Health Indicators Among Ontario Adults 1977-2011 (CAMH Research Document Series no. 35). Toronto: Centre for Addiction and Mental Health. 2012. Available at: http://www.camh.ca/en/research/news_and_publications/Pages/camh_monitor.aspx (accessed 4 February 2013) (Archived at http://www.webcitation.org/6EBgKMYHG on 4 February 2013).
37. Fischer B., Bibby M., Bouchard M. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction 2010; 105: 2062-2070.
38. Pederson K. The British Columbia Coroners Service: a perspective on prescription opiates. 2011. Available at http://www.csam.org/files/Pederson_-_BC_Coroners.pdf (accessed 4 February 2013) (Archived at http://www.webcitation.org/6EBgRziWq on 4 February 2013).
39. Paulozzi L., Baldwin G., Franklin G., Kerlikowske R. G., Jones C. M., Ghiya N. etal. CDC grand rounds: prescription drug overdoses-a U.S. epidemic. Morb Mortal Wkly Rep 2012; 61: 10-13.
40. Inciardi J. A., Surratt H. L., Cicero T. J., Beard R. A. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med 2009; 10: 537-548.
41. Lohman D., Schleifer R., Amon J. J. Access to pain treatment as a human right. BMC Med 2010; 8: 8.
42. Chou R., Fanciullo G., Fine P., Adler J., Ballantyne J., Davies P. etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130.
43. Brennan F., Carr D. B., Cousins M. Pain management: a fundamental human right. Anesth Analg 2007; 105: 205-221.
44. Lasser K. E., Himmelstein D. U., Woolhandler S. Access to care, health status, and health disparities in the United States and Canada: results of a cross-national population-based survey. Am J Public Health 2006; 96: 1300-1307.
45. Breivik H., Cherny N., Collett B., de Conno F., Filbet M., Foubert A. J. etal. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009; 20: 1420-1433.
46. Breivik H., Collett B., Ventafridda V., Cohen R., Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333.
47. Deandrea S., Montanari M., Moja L., Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19: 1985-1991.
48. Lynch M. E. The need for a Canadian Pain Strategy. Pain Res Manag 2011; 16: 77-80.
49. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2012. Sales no. E.12.XI.1. Vienna: United Nations Publications; 2012. Available at: http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf (accessed 4 February 2013) (Archived at http://www.webcitation.org/6EBgY1Fj7 on 4 February 2013).
50. Degenhardt L., Chiu W. T., Sampson N., Kessler R. C., Anthony J. C., Angermeyer M. etal. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008; 5: e141.
51. Vega W. A., Aguilar-Gaxiola S., Andrade L., Bijl R., Borges G., Caraveo-Anduaga J. J. etal. Prevalence and age of onset for drug use in seven international sites: results from the international consortium of psychiatric epidemiology. Drug Alcohol Depend 2002; 68: 285-297.
52. Rose N. Neurochemical selves. Society 2003; 41: 46-59.
53. Zito J. M., Safer D. J., de Jong-van den Berg L. T. W., Janhsen K., Fegert J. M., Gardner J. F. etal. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008; 2: 26-34.
54. Zito J. M., Tobi H., de Jong-van den Berg L. T. W., Fegert J. M., Safer D. J., Janhsen K. etal. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 2006; 15: 793-798.
55. Okie S. ADHD in adults. N Engl J Med 2006; 354: 2637-2641.
56. Almasi E. A., Stafford R. S., Kravitz R. L., Mansfield P. R. What are the public health effects of direct-to-consumer drug advertising? PLoS Med 2006; 3: e145.
57. Vuckovic N., Nichter M. Changing patterns of pharmaceutical practice in the United States. Soc Sci Med 1997; 44: 1285-1302.
58. Kelner M., Wellman B., Boon H., Welsh S. Responses of established healthcare to the professionalization of complementary and alternative medicine in Ontario. Soc Sci Med 2004; 59: 915-930.
59. Tsao J. C. I., Zeltzer L. K. Complementary and alternative medicine approaches for pediatric pain: a review of the state-of-the-science. Evid Based Complement Alternat Med 2005; 2: 149-159.
60. The Commonwealth Fund, Thomson S., Osborn R., Squires D., Reed S. J., editors. International Profiles of Health Care Systems, 2011. Publication no. 1562. New York: Commonwealth Fund; 2011. Available at: http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf (accessed 4 February 2013) (Archived at http://www.webcitation.org/6EBgY1Fj7 on 4 February 2013).
61. Deyo R. A., Mirza S. K., Turner J. A., Martin B. I. Overtreating chronic back pain: time to back off? J Am Board Fam Med 2009; 22: 62-68.
62. Schwartz R. K., Soumerai S. B., Avorn J. Physician motivations for nonscientific drug prescribing. Soc Sci Med 1989; 28: 577-582.